Welcome to our dedicated page for Zevia PBC SEC filings (Ticker: ZVIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevia PBC filings document the public-company disclosures of a Delaware public benefit corporation focused on zero-sugar, clean-label beverages. Form 8-K reports furnish quarterly and annual earnings releases, Regulation FD investor presentations, board appointments and committee assignments, and material agreements tied to the company’s capital structure.
Proxy materials describe annual meeting matters such as director elections, auditor ratification, board structure, committee oversight and stockholder voting procedures. Other filings address the company’s Class A common stock, its wholly owned subsidiary Zevia LLC, and equity distribution arrangements used for at-the-market offering capacity.
Divisadero Street Capital Management, LP and related entities report a 4.8% passive stake in Zevia PBC’s Class A common stock. As of December 31, 2025, they beneficially own 3,213,961 shares with shared voting and dispositive power and no sole authority.
All shares are held for advisory clients of Divisadero Street Capital Management, LP, and no individual client is deemed to own more than 5% of the class. The filers certify the position is not held to change or influence control of Zevia.
Topline Capital Management, LLC and related reporting persons disclosed beneficial ownership of 5,951,196 shares of Zevia PBC Class A common stock, representing 8.8% of the class. The shares are held by Topline Capital Partners, LP, with Topline Capital Management having sole voting and dispositive power over this position.
Individual manager Collin McBirney is deemed to share voting and dispositive power over the same shares but reports no sole authority. The filers state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Zevia PBC.
CDP Investissements Inc. and Caisse de depot et placement du Quebec filed Amendment No. 3 to their Schedule 13D on Zevia PBC, reporting beneficial ownership of 13,550,428 shares of Class A Common Stock, representing 20.1% of the class.
They report shared voting and dispositive power over all 13,550,428 shares and no sole power. The ownership percentage is based on 67,389,166 Zevia Class A shares outstanding as of October 31, 2025, as disclosed in Zevia’s Form 10-Q for the quarter ended September 30, 2025.
The amendment updates identity and background information for controlling persons and restates their interest in Zevia’s securities. It also notes that transactions in the last 60 days are listed in Annex B and, other than those, no additional trades were made during that period.
CDP Investissements Inc., a wholly owned subsidiary of Caisse de dépôt et placement du Québec and a 10% owner of Zevia PBC, reported selling 3,500,000 shares of Zevia Class A common stock on January 27, 2026 at $2 per share.
After this transaction, CDP Investissements Inc. reported beneficial ownership of 13,550,428 Class A shares, held directly. CDPQ may be deemed to beneficially own these shares through its 100% ownership of CDP Investissements Inc.
CDP Investissements Inc., a wholly owned subsidiary of Caisse de dépôt et placement du Québec (CDPQ), sold 2,971,664 shares of Zevia PBC Class A Common Stock at $2.73 per share on September 30, 2025. After this transaction, CDP directly held 17,050,428 shares. The Form 4 is filed jointly by CDPQ and CDP, with CDPQ potentially deemed a beneficial owner through its subsidiary relationship.
Zevia PBC has a shareholder planning to sell Class A common stock under Rule 144. The notice covers 3,500,000 shares with an aggregate market value of $7,175,000, to be sold through BMO Capital Markets on the NYSE, with 67,389,166 shares outstanding.
The shares trace back to a December 21, 2020 cash purchase of Series E Preferred Units in Zevia LLC, which were later converted into Zevia PBC Class A common stock in connection with the company’s IPO.
Zevia PBC director Suzanne Saltzman Ginestro filed a Form 3 indicating she currently holds no Zevia securities. The filing lists her relationship to the company as a director and confirms that no non-derivative or derivative securities are beneficially owned. The event date for this initial ownership report is noted as 01/07/2026.
Zevia PBC reported changes to its board of directors. The board appointed Suzanne Ginestro as an independent Class II director effective January 7, 2026, with her term running until the company’s 2026 annual meeting of stockholders, when she will be eligible for re-election. She will also serve on the board’s Compensation Committee and receive the standard compensation provided to non-employee directors, as described in the company’s 2025 annual meeting proxy statement.
The company also disclosed that director Justin Shaw notified Zevia on January 7, 2026 that he will step down from the board effective February 24, 2026. His resignation is not due to any disagreement with the company or the board over operations, policies, or practices. Zevia expects Ms. Ginestro to enter into its standard director and officer indemnification agreement and stated there are no related-party transactions requiring disclosure.
Zevia PBC (ZVIA) — Form 4 insider transaction: A director reported selling 200,000 shares of Class A Common Stock on 11/10/2025 at a weighted average price of $2.6439, with sales executed between $2.605 and $2.70. Following the sale, the director beneficially owns 1,595,417 shares, including 71,827 RSUs. The filing notes RSUs of 148,417 vest in 1/4 increments on each anniversary of March 17, 2022, and 34,722 RSUs vest on the earlier of June 12, 2026 or the 2026 annual meeting, with settlement within 30 days of vesting.
Zevia PBC (ZVIA) reported a Form 144 notice indicating a proposed sale of 200,000 shares of Class A common stock. The filing lists Merrill Lynch as broker, an approximate sale date of 11/10/2025, and trading on the NYSE, with an aggregate market value of $528,782.54.
The shares were acquired through vesting of restricted stock unit awards granted under the issuer’s equity compensation plan across multiple dates, matching the 200,000 shares to be sold. The filing notes 67,389,166 shares outstanding.